Achiko AG (SIX: ACHI.SW) is developing disruptive diagnostic solutions that puts people first. Invented by Dr Michael Edel, the company’s flagship product is a fast, friendly, affordable and accurate Covid-19 test with a companion app. The test and companion app were launched in Indonesia in mid-2021 and AptameXTM received the CE Mark in the European Union in May 2022.
Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameXTM and companion health apps via its digital mobile health technology division, Teman SehatTM. The AptameXTM DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameXTM and Teman SehatTM, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.
Headquartered in Zurich, Achiko has offices in Jakarta and Singapore.
Achiko AG is listed on the SIX Swiss Exchange
SWX: ACHI, ISIN CH0522213468